Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.32 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7095029 | 1.00 | GABBR2 (0.34) | GABBR2GABBR1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL7093048 | 0.86 | GSK3B (0.31) | — | |
| SCHEMBL7093047 | 0.86 | GSK3B (0.31) | — | |
| SCHEMBL13656879 | 0.79 | GABBR2 (0.44) | GABBR2GABBR1ALDH1A1 | |
| SCHEMBL7155129 | 0.79 | GABBR2 (0.44) | GABBR2GABBR1ALDH1A1 | |
| SCHEMBL7090167 | 0.77 | ERBB2 (0.41) | GABBR2GABBR1ALDH1A1 | |
| SCHEMBL7090165 | 0.77 | ERBB2 (0.41) | GABBR2GABBR1ALDH1A1 | |
| SCHEMBL6306524 | 0.68 | GABBR2 (0.44) | GABBR2GABBR1ALDH1A1 | |
| SCHEMBL7093589 | 0.67 | ALDH1A1 (0.38) | GABBR2GABBR1ALDH1A1 | |
| SCHEMBL7093590 | 0.67 | ALDH1A1 (0.38) | GABBR2GABBR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030121113-A1 | Oxobenzofuranylide-dihydroindolone | NESVADBA PETER (CH) | 2003-07-03 | — | — | US | disclosed |
| US-6503937-B1 | Coloring agents for high molecular weight materials such as polymers | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-01-07 | — | — | US | disclosed |
| EP-1123289-B1 | OXOBENZOFURANYLIDE-DIHYDROINDOLONES | CIBA SC HOLDING AG (CH) | 2002-11-27 | — | — | EP | disclosed |
| EP-1123289-A1 | OXOBENZOFURANYLIDE-DIHYDROINDOLONE | Ciba SC Holding AG (CH) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000024736-A1 | OXOBENZOFURANYLIDE-DIHYDROINDOLONE | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030121113-A1 | Oxobenzofuranylide-dihydroindolone | CYP1B1, CYP1A1, ECI1 | GABBR2 1419/4885GABBR1 1506/4885ALDH1A1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.